Is a fundamental reassessment starting?
The focus on core competencies and the prospect of increasing demand in preclinical development is likely to positively influence the stock price development!
Just – Evotec Biologics is still a potentially underestimated growth driver!
Reading Time: 1 minute
Evotec (i.) is currently undergoing a transformation process. The company recently announced that it aims to focus more specifically on its core competencies in drug research and preclinical development with a two-pillar strategy. I believe this makes absolute sense, as numerous patents for medications will expire by 2030. This will, in turn, drive demand in early-phase research. This is precisely where Evotec can showcase its strengths in R&D. These strengths are particularly evident in areas such as protein degradation, stem cell platforms,...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
